Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 106

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 106
---
 not be possible for investors to effect service
of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments
predicated upon the civil liability provisions of the U.S. federal securities laws.

The United States and the
United Kingdom do not currently have a treaty providing for the reciprocal recognition and enforcement of judgments (other than arbitration
awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or
not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in England and Wales. In addition,
uncertainty exists as to whether the English and Welsh courts would entertain original actions brought in England and Wales against us
or our directors or executive officers predicated upon the securities laws of the United States or any state in the United States. Any
final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England
and Wales as a cause of action in itself and sued upon as a debt so that no retrial of the issues would be necessary, provided that certain
requirements are met consistent with English law and public policy. Whether these requirements are met in respect of a judgment based
upon the civil liability provisions of the U.S. securities laws is an issue for the English court making such decision. If an English
court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available
for this purpose.

As a result, U.S. investors
may not be able to enforce against us or our executive officers, board of directors or certain experts named herein who are residents
of the United Kingdom or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters,
including judgments under the U.S. federal securities laws.

We intend to operate so as to be treated exclusively as a resident of the United Kingdom for tax purposes, but the relevant tax authorities may treat us as also being a resident of another jurisdiction for tax purposes.

Under current English law,
the decisions of the English courts and the published practice of His Majesty’s Revenue and Customs suggest that we are likely to
be regarded as being a United Kingdom resident and should remain so if, as we intend that, (i) all major meetings of our Board of Directors
and most routine meetings are held in the United Kingdom with a majority of directors present in the United Kingdom